

## Selectivity of the collagen-binding integrin inhibitors, TC-I-15 and obtustatin

Emma J. Hunter<sup>a</sup>, Samir W. Hamaia<sup>a</sup>, Donald Gullberg<sup>b</sup>, Jean-Daniel Malcor<sup>a</sup>, Richard W. Farndale<sup>a,\*</sup>

<sup>a</sup> Department of Biochemistry, University of Cambridge, Downing Site, Cambridge CB2 1QW, UK

<sup>b</sup> Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009 Bergen, Norway

### ARTICLE INFO

Editor: Dr. Lawrence Lash

#### Keywords:

Integrin  
Collagen peptides  
Obtustatin  
TC-I-15  
Cell adhesion  
C2C12

### ABSTRACT

Integrins are a family of 24 adhesion receptors which are both widely-expressed and important in many pathophysiological cellular processes, from embryonic development to cancer metastasis. Hence, integrin inhibitors are valuable research tools which may have promising therapeutic uses. Here, we focus on the four collagen-binding integrins  $\alpha1\beta1$ ,  $\alpha2\beta1$ ,  $\alpha10\beta1$  and  $\alpha11\beta1$ . TC-I-15 is a small molecule inhibitor of  $\alpha2\beta1$  that inhibits platelet adhesion to collagen and thrombus deposition, and obtustatin is an  $\alpha1\beta1$ -specific disintegrin that inhibits angiogenesis. Both inhibitors were applied in cellular adhesion studies, using synthetic collagen peptide coatings with selective affinity for the different collagen-binding integrins and testing the adhesion of C2C12 cells transfected with each. Obtustatin was found to be specific for  $\alpha1\beta1$ , as described, whereas TC-I-15 is shown to be non-specific, since it inhibits both  $\alpha1\beta1$  and  $\alpha11\beta1$  as well as  $\alpha2\beta1$ . TC-I-15 was 100-fold more potent against  $\alpha2\beta1$  binding to a lower-affinity collagen peptide, suggestive of a competitive mechanism. These results caution against the use of integrin inhibitors in a therapeutic or research setting without testing for cross-reactivity.

### 1. Introduction

Integrins are a family of glycoprotein transmembrane cell adhesion receptors that exist as  $\alpha/\beta$  heterodimers. In humans, there are 18  $\alpha$ -subunits and 8  $\beta$ -subunits that combine to form 24 different integrins (Arnaout et al., 2005; Barczyk et al., 2010; Hynes, 2002). Integrin expression is widespread but cell type-dependent, and most integrins bind a selection of extracellular matrix (ECM) components or cell-surface ligands. It is thought that cells express an excess of  $\beta$ -subunits and the expression of  $\alpha$ -subunits determines surface receptor expression (Santala and Heino, 1991). They play essential roles in embryonic development, cell migration, proliferation and angiogenesis, and have been implicated in tumorigenesis and inflammation (Santala and Heino, 1991; Arnaout, 2016; van der Flier et al., 2010; San Antonio et al., 2009; Pozzi et al., 1998; Zhang et al., 2008; Senger et al., 2002; da Silva et al., 2010; Sottnik et al., 2013; Alique et al., 2014). Their primary function is to facilitate adhesion of cells to each other and to the ECM, but also to take part in matrix assembly (Muslime et al., 2021). Integrin-mediated signalling is essential for cell survival and many cell responses to growth factors are dependent on cell adhesion to a substrate via

integrins (Barczyk et al., 2010; Meredith Jr. and Schwartz, 1997; Schwartz and Assoian, 2001; Byzova et al., 2000). As a consequence, many cell types must adhere to the matrix through integrins to survive (Schwartz and Assoian, 2001; Assoian, 1997).

Both the  $\alpha$  and  $\beta$  subunits have a large extracellular N-terminal 'head' domain, a transmembrane domain and a small cytoplasmic C-terminal 'tail' (Arnaout et al., 2005; Barczyk et al., 2010; Hynes, 2002; Takada et al., 2007). By linking the ECM to the cytoskeleton, integrins mediate signal transduction from the environment, activating downstream signalling pathways such as focal adhesion kinases, talin and Src family kinases (Huvencens and Danen, 2009; Tadokoro et al., 2003; Calderwood et al., 1999). They form bi-directional signalling hubs that coordinate signals from several pathways (Arnaout et al., 2005; Giancotti and Ruoslahti, 1999) and form clusters with co-receptors and other integrins to amplify and modulate signals (Welf et al., 2012).

The four collagen-binding integrins,  $\alpha1\beta1$ ,  $\alpha2\beta1$ ,  $\alpha10\beta1$  and  $\alpha11\beta1$  all adhere to the GFOGER motif found primarily in collagens I and II, and to GLOGEN that is unique to collagen III.  $\alpha2\beta1$  and  $\alpha11\beta1$  adhere more strongly to GFOGER while  $\alpha1\beta1$  and  $\alpha10\beta1$  adhere more strongly to GLOGEN. Triple-helical peptides (THPs) containing these motifs have

\* Corresponding author.

E-mail address: [rwf10@cam.ac.uk](mailto:rwf10@cam.ac.uk) (R.W. Farndale).

<https://doi.org/10.1016/j.taap.2021.115669>

Received 13 May 2021; Received in revised form 29 July 2021; Accepted 2 August 2021

Available online 5 August 2021

0041-008X/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

been synthesised and are used throughout this study (Emsley et al., 2000; Farnsdale, 2019; Knight et al., 2000; Zhang et al., 2003). Integrins  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  are widely expressed, whereas  $\alpha 10\beta 1$  is expressed primarily in chondrocytes (Barczyk et al., 2010; Takada et al., 2007) and  $\alpha 11\beta 1$  is expressed in fibroblasts, subsets of mesenchymal stem cells and subsets of cancer-associated fibroblasts (Zeltz and Gullberg, 2016; Popova et al., 2007; Popov et al., 2011; Shen et al., 2019; Zeltz et al., 2019; Zeltz et al., 2020). The range of pathways involving integrins highlights their importance in tissue function and homeostasis across a variety of organs. For example, whole organism ablation of  $\beta 1$  integrin in mice leads to embryonic fatal phenotype before E5.5 (Fassler and Meyer, 1995). Similar ablation of  $\alpha 1$  or  $\alpha 2$  subunits has a much less severe effect, with  $\alpha 1$ -null mice producing viable offspring with minor defects in collagen synthesis and angiogenesis (Gardner et al., 1996; Pozzi et al., 2000), whilst  $\alpha 2$ -null mice show delayed platelet aggregation (Chen et al., 2002). Both  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  enhance cancer cell migration and metastasis (Primac et al., 2019), for example, by upregulating matrix metalloproteinase synthesis via MAPK signalling (Ibaragi et al., 2011). Integrin  $\alpha 2\beta 1$  also promotes prostate cancer metastasis to the skeleton, resulting in a poor prognosis for patients (Sottnik et al., 2013). Unlike  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$ , which in tumours are expressed in both neoplastic and vascular cells,  $\alpha 11\beta 1$  is restricted to cancer-associated fibroblasts, and in a breast cancer model, restricts both tumour growth and metastasis (Primac et al., 2019). Understanding the inhibition of collagen-binding integrins is central to therapeutic targeting of integrins in these and other pathologies.

Nine of the integrins, including  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 10$  and  $\alpha 11$ , contain an  $\alpha I$ -domain, an insertion of about 200 amino acids in the  $\beta$  propeller structure of the  $\alpha$  subunit head. The  $\beta$  subunits contain a similar  $\beta I$ -domain, and together, these I-domains regulate the activation status of the integrin (Arnaout et al., 2005; Shimaoka et al., 2002). The  $\alpha I$ -domains determine ligand specificity despite their high homology; the rest of the subunit is more variable (Luo et al., 2007). The  $\alpha I$ -domains adopt a Rossman fold with a five-stranded  $\beta$ -sheet surrounded by seven  $\alpha$ -helices. Both the  $\alpha$  and  $\beta I$ -domain contain a metal-ion-dependent adhesion site (MIDAS) that co-ordinates  $Mg^{2+}$  to which acidic residues, such as glutamate in the GFOGER motif, can bind. Conformational changes in the  $\alpha I$ -domain are required to allow it to bind its ligand (Arnaout et al., 2005; Emsley et al., 2000; Shimaoka et al., 2002; Luo et al., 2007; Emsley et al., 1997). In the inactive conformation, the MIDAS is protected by a short C-helix. Upon integrin activation, the MIDAS reorganises and helix 7 translocates towards the  $\alpha$ - $\beta$  interface. This results in the relocation of the short C-helix onto helix 6, revealing the  $Mg^{2+}$  ion in a shallow groove that can accept the glutamate-containing motif from collagen or THPs (Emsley et al., 2000; Dickeson and Santoro, 1998; Hamaia et al., 2017). Communication occurs between residue E336, at the base of  $\alpha I$ -domain helix 7, and the  $\beta I$ -domain MIDAS. The downward motion of helix 7 leads to reorganisation of the  $\alpha I$  MIDAS and C-helix, and to activation of collagen-binding (Alonso et al., 2002; Yang et al., 2004).

Integrin inhibitors have therapeutic potential as well as being valuable research tools, and their study is therefore of great importance. The small molecule inhibitor, TC-I-15 (compound 15 in (Miller et al., 2009)) is considered to inhibit  $\alpha 2\beta 1$  by binding to the  $\beta I$ -domain MIDAS (Miller et al., 2009). The free carboxylate of the TC-I-15 dipeptide scaffold interacts with the MIDAS  $Mg^{2+}$  ion, alongside Y122 and N215, (ITB1-HUMAN Uniprot sequence) to block its ligation by E336 and so preventing the downward movement of helix 7. Consequently, the  $\alpha$  subunit MIDAS remains concealed behind the C-helix and the integrin is stabilised in the inactive conformation. In platelets, this results in potent inhibition of platelet adhesion to collagen and the inhibition of subsequent thrombosis in animal models (Miller et al., 2009). TC-I-15 reportedly has no effect on the constitutively active E318A mutation of  $\alpha 2\beta 1$  (Miller et al., 2009). E318 is located at the top of helix 7, forming a salt bridge with R288 in the C-helix which must be broken to permit activation (Emsley et al., 2000). Thus, in E318A, helix 7 is decoupled

from the upper surface of the  $\alpha I$  domain which can reorganise independently of the  $\beta I$ -domain, and so E318A cannot be stabilised in the inactive conformation by TC-I-15.

Disintegrins are a family of integrin inhibitors derived from snake venoms (Arruda Macedo et al., 2015; Marcinkiewicz et al., 2003; Daidone et al., 2013). They are small cysteine-rich polypeptides, divided into several sub-groups based on their size or specificity. Disintegrins contain an integrin binding loop that, generally, competes directly with the natural ligand at its  $\beta$ -subunit binding site, and to fulfil this function, the integrin binding loop contains an RGD motif (Arruda Macedo et al., 2015). Similar motifs include MLD, VGD, KGD, and WGD, with each motif conferring a degree of integrin selectivity (see Table 1). Obtustatin, a KTS-disintegrin of just 41 residues, differs in its integrin-binding loop which contains WKTSLSLTSY (Marcinkiewicz et al., 2003; Daidone et al., 2013), where the threonine residue (T22) is essential for  $\alpha 1\beta 1$  binding and the adjacent leucine (L24) contributes to high affinity (Kisiel et al., 2004). Two further KTS-disintegrins, viperistatin and lebestatin, and an RTS-containing disintegrin, jerdostatin, are also potent inhibitors of  $\alpha 1\beta 1$  (Kisiel et al., 2004), although where these disintegrins bind to  $\alpha 1\beta 1$  is not known. Obtustatin inhibits cellular, membrane-bound  $\alpha 1\beta 1$  and the isolated full length  $\alpha 1\beta 1$  but has no effect on recombinant  $\alpha I$ -domains (Marcinkiewicz et al., 2003). The specificity of obtustatin, together with the absence of an acidic residue in its integrin-binding loop, suggests that obtustatin must interact with the  $\alpha 1$  subunit, most likely as well as with the  $\beta 1$  subunit, close to the interface between the two. Obtustatin has been used to inhibit angiogenesis in vitro and in vivo in chick chorioallantoic membrane assays (Marcinkiewicz et al., 2003). Obtustatin also reduced tumour development by 50% in the mouse Lewis lung carcinoma model, and blocked melanoma growth in mice (Marcinkiewicz et al., 2003; Brown et al., 2008).

Neither of these two inhibitors, TC-I-15 and Obtustatin, has been tested on the more recently-characterised integrins,  $\alpha 10\beta 1$  or  $\alpha 11\beta 1$ . Here, we tested their cross-reactivity with other collagen-binding integrins using recombinant integrin  $\alpha I$ -domains, HT1080 cells that express only  $\alpha 2\beta 1$  and C2C12 cells that have been stably transfected to express only  $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$ ,  $\alpha 10\beta 1$  or  $\alpha 11\beta 1$ . A previously-characterised inhibitor of  $\alpha 2\beta 1$ , monoclonal antibody 6F1, was also tested for comparison. The commercially-available small molecule  $\alpha 2\beta 1$  inhibitor, TC-I-15, was found to be non-specific as it also exerted an inhibitory effect on  $\alpha 1\beta 1$  and, at much higher concentrations,  $\alpha 11\beta 1$ . Further, TC-I-15 was found to have no effect on  $\alpha 10\beta 1$  or purified  $\alpha 3\beta 1$ . However, Obtustatin was found to inhibit only  $\alpha 1\beta 1$  of the four collagen-binding integrins. This highlights the importance of rigorously testing inhibitors for cross-reactivity before they can be used specifically.

## 2. Materials and methods

Integrin  $\alpha I$ -domains were expressed as described (Siljander et al., 2004; Hamaia et al., 2012). TC-I-15 (4527/10), Obtustatin (4664/100 U) and  $\alpha 3\beta 1$  (2840-A3-050) were purchased from R&D technologies. Placental laminin-511 was purchased from Sigma L6274 (Wondimu et al., 2006). TC-I-15 was dissolved in NaOH (typically 220  $\mu$ M) to obtain a final molar ratio of 1:1.1 (TC-I-15:NaOH). NaOH alone was used as a vehicle control for TC-I-15 whereas obtustatin and 6F1 were

**Table 1**

A summary of the specificities of different motifs found on the integrin binding loop of various disintegrins. Adapted from (Arruda Macedo et al., 2015) and (Assumpcao et al., 2012)

Motif	Integrins targeted
RGD	$\alpha 3\beta 1$ , $\alpha 4\beta 1$ , $\alpha 5\beta 1$ , $\alpha 6\beta 1$ , $\alpha 7\beta 1$ , $\alpha 8\beta 1$ , $\alpha v\beta 1$ , $\alpha v\beta 3$ , $\alpha IIb\beta 3$ , and $\alpha v\beta 5$
MLD	$\alpha 3\beta 1$ , $\alpha 4\beta 1$ , $\alpha 5\beta 1$ , $\alpha 6\beta 1$ , $\alpha 7\beta 1$ , $\alpha 9\beta 1$ , $\alpha IIb\beta 3$ , and $\alpha 4\beta 7$
VGD/MGD	$\alpha 5\beta 1$
KGD	$\alpha IIb\beta 3$
WGD	$\alpha 5\beta 1$ , $\alpha v\beta 3$ and $\alpha IIb\beta 3$
KTS/RTS	$\alpha 1\beta 1$

suspended in PBS. 6F1 was the generous gift of Dr. B. Collier, NY, USA.

### 2.1. Cell culture

C2C12s and HT1080s were grown in Lifetech DMEM/10% FBS and 1% penicillin/streptomycin. All cells were maintained under sterile conditions at 37 °C, 5% CO<sub>2</sub>. Cells were passaged using Trypsin/EDTA at 37 °C for 5 min and DMEM/10% FBS to quench the trypsin. C2C12 cells were transfected as described previously (Tiger et al., 2001). The C2C12- $\alpha$ 10 clone was kindly made available by Dr. Evy Lundgren-Åkerlund, Xintela AB, Sweden.

### 2.2. Cellular static adhesion assays

Immulon 2HB 96-well plates were coated with 100  $\mu$ l per well of peptides at 10  $\mu$ g/ml in 0.01 M acetic acid overnight at 4 °C. After 3  $\times$  200  $\mu$ l/well PBS washes, plates were blocked with 200  $\mu$ l/well filtered 3% BSA in PBS at RT for 1 h. Plates were washed, and 20,000 cells/well were added at room temperature (RT) for 1 h in serum-free media with 5 mM MgCl<sub>2</sub> and varying concentrations of inhibitor. Unbound cells were washed away with 3 $\times$  washes of 200  $\mu$ l/well PBS. Adherent cells were lysed with 50  $\mu$ l per well of 2% Triton X-100 in water for 1 h at RT. Cell number was quantified using 50  $\mu$ l per well of the Roche cytotoxicity LDH kit. The catalyst and substrate solutions of the kit were mixed at a ratio of 1:45 and 50  $\mu$ l was added to the wells to detect LDH in the cell lysate. A<sub>490</sub> was read in a SpectraMax 190 microplate reader (Molecular Devices). Each condition was performed in triplicate, with at least three independent repeats.

### 2.3. Protein static adhesion assays

Immulon 2HB 96-well plates were coated with 100  $\mu$ l per well of peptides at 10  $\mu$ g/ml in 0.01 M acetic acid. After 3  $\times$  200  $\mu$ l/well washes with washing buffer (1 mg/ml BSA in TBS), plates were blocked with 200  $\mu$ l per well of filtered 3% BSA in TBS for 1 h at RT.  $\alpha$ I-domains were added at 10  $\mu$ g/ml in washing buffer for 1 h at RT with 5 mM MgCl<sub>2</sub> and various concentrations of inhibitor as stated. After 3  $\times$  200  $\mu$ l/well washes with washing buffer, anti-GST detection antibody (GE Healthcare HRP conjugated anti-GST GERPN1236) were added for 1 h. Plates were washed 4 $\times$  with 200  $\mu$ l per well of washing buffer and bound protein was quantified using the Pierce™ TMB Substrate Kit. The colorimetric reaction was stopped with an equal volume of 1 M H<sub>2</sub>SO<sub>4</sub> and A<sub>450</sub> was read as above. Each condition was performed in triplicate and each experiment was repeated at least three times using different preparations of proteins.

### 2.4. Collagen peptides

Peptides containing the sequences GFOGER or GLOGEN (single amino acid nomenclature where O is hydroxyproline) were synthesised as C-terminal amides, and assembled as triple-helical homotrimers, as described previously (Knight et al., 2000; Raynal et al., 2006). Peptides contain a binding motif (such as GFOGER) flanked on either side by five GPP repeats and a GPC triplet at both the N- and C-termini. Peptides were synthesised using solid phase Fmoc peptide chemistry on a CEM Liberty Blue microwave-assisted synthesiser. Peptides were then cleaved from the resin beads, purified by preparative reverse-phase high performance liquid chromatography, freeze dried and characterised by mass spectrometry. Peptides were dissolved at 5 mg/ml in 0.01 M acetic acid, heated to 70 °C for 5 min and allowed to cool overnight to enable triple helix folding. Peptides were diluted from this stock solution to 10  $\mu$ g/ml in 0.01 M acetic acid for the coating of empty tissue culture wells prior to experiments. The peptide GPP10 (sequence: GPC(GPP)<sub>10</sub>GPC-amide) is used as a negative control. The GPP repeats adopt triple-helical structure but the sequence is inert, with no binding motifs present.

### 2.5. Statistical analysis

PRISM 8.2.1 or later (GraphPad, San Diego, CA, USA), was used for all statistical tests. For single concentration studies one-way ANOVA was used with Sidak's multiple comparisons test to compare means for each condition with the appropriate control. Means  $\pm$  SD are shown in all data sets. Inhibition curves were analysed using nonlinear regression comparing each data set with either a horizontal line model (null hypothesis, no inhibition) or three-parameter dose-response curve (inhibition occurs). Three-parameter curves were constrained with lower value <0.1, reflecting inhibition of adhesion to baseline GPP10 values, and IC<sub>50</sub> > 0.


## 3. Results

### 3.1. Integrin $\alpha$ I-domain adhesion to collagen peptides is unaffected by TC-I-15 and Obtustatin

To confirm that these inhibitors have no effect on isolated  $\alpha$ I-domains, GST-tagged  $\alpha$ I-domains were tested in static adhesion assays where plates had been coated with either GLOGEN (for the  $\alpha$ 1 I-domain) or GFOGER (for the  $\alpha$ 2 I-domain) in the presence or absence of the inhibitors obtustatin, 6F1 and TC-I-15. Previous work in this laboratory established that GFOGER is a strong ligand and GLOGEN a moderate ligand for  $\alpha$ 2 $\beta$ 1 whereas GLOGEN is a strong ligand and GFOGER a moderate ligand for  $\alpha$ 1 $\beta$ 1 (Farndale, 2019; Knight et al., 2000; Farndale et al., 2008). The  $\alpha$ 2 $\beta$ 1 inhibitory antibody, 6F1, was also included for comparison (Collier et al., 1989). Fig. 1A and B show levels of adhesion after inhibition. Antibody 6F1 was a potent inhibitor of the  $\alpha$ 2 I-domain adhesion to GFOGER (control mean = 2.51  $\pm$  0.3; 6F1 mean = 0.29  $\pm$  0.056,  $p$  < 0.0001) but not the  $\alpha$ 1 I-domain adhesion to GLOGEN, confirming its specificity for  $\alpha$ 2 $\beta$ 1. This confirms that, whereas 6F1 directly targets the free  $\alpha$ I-domain, obtustatin and TC-I-15 are not able to do so, in agreement with the literature.

### 3.2. In C2C12 cells, TC-I-15 inhibits adhesion of $\alpha$ 1 $\beta$ 1, $\alpha$ 2 $\beta$ 1 and $\alpha$ 11 $\beta$ 1, but not $\alpha$ 10 $\beta$ 1, to collagen peptides

Next, to test the effects of these inhibitors on the full-length integrin receptors, C2C12 cells that have been stably transfected to express one of the four integrins were used in static adhesion assays. Plates were coated with GFOGER, GLOGEN or GPP10 (as the negative control) and inhibition dose curves for TC-I-15 and Obtustatin were carried out. Fig. 2 shows the dose curves for TC-I-15-mediated inhibition of the adhesion of C2C12 cells expressing  $\alpha$ 1 $\beta$ 1,  $\alpha$ 2 $\beta$ 1,  $\alpha$ 10 $\beta$ 1 or  $\alpha$ 11 $\beta$ 1 (Fig. 2A-2D respectively). Non-linear regression was used to analyse the curves, as described in Materials and Methods. Firstly, TC-I-15 inhibited  $\alpha$ 2 $\beta$ 1-expressing C2C12 cell adhesion in dose-dependent manner, as anticipated (for GFOGER, IC<sub>50</sub> = 26.8  $\mu$ M, R<sup>2</sup> = 0.9066,  $P$  < 0.0001 and for GLOGEN IC<sub>50</sub> = 0.4  $\mu$ M, R<sup>2</sup> = 0.9943,  $P$  < 0.001), but it also inhibited  $\alpha$ 1 $\beta$ 1 (for GFOGER, IC<sub>50</sub> = 23.6  $\mu$ M, R<sup>2</sup> = 0.98,  $P$  < 0.001 and for GLOGEN IC<sub>50</sub> = 24.4  $\mu$ M, R<sup>2</sup> = 0.94,  $P$  < 0.001). At higher concentrations,  $\alpha$ 11 $\beta$ 1 was also inhibited (for GFOGER, IC<sub>50</sub> = 3177  $\mu$ M, R<sup>2</sup> = 0.80,  $P$  < 0.001 and for GLOGEN IC<sub>50</sub> = 177  $\mu$ M, R<sup>2</sup> = 0.70,  $P$  < 0.001). For TC-I-15-mediated inhibition of  $\alpha$ 10 $\beta$ 1, and all the control conditions, the preferred statistical model was a horizontal line, i.e., no inhibition was seen. Secondly, the degree of inhibition was peptide-dependent for  $\alpha$ 2 $\beta$ 1 and  $\alpha$ 11 $\beta$ 1, but not for  $\alpha$ 1 $\beta$ 1. For  $\alpha$ 2 $\beta$ 1, complete inhibition of adhesion was seen at very low concentrations of TC-I-15 for the lower-affinity peptide, GLOGEN, but a much higher concentration of TC-I-15 was needed to achieve the same effect for adhesion to GFOGER. A similar substrate-dependence was seen with  $\alpha$ 11 $\beta$ 1. In contrast, for  $\alpha$ 1 $\beta$ 1 the potency was the same for both peptides tested and the IC<sub>50</sub> values are very similar.



**Fig. 1.** Inhibition of binding of recombinant  $\alpha$ I-domains to peptide coatings. Adhesion of A,  $\alpha$ 1 I-domain to GLOGEN and B,  $\alpha$ 2 I-domain to GFOGER, was measured using anti-GST-HRP conjugated antibody as described in Materials and methods, and is shown as mean  $A_{450} \pm$  SD. TC-I-15 (200  $\mu$ M), Obtustatin (20  $\mu$ M) or 6F1 (10  $\mu$ g/ml) were used as indicated. “TC-I-15 ctrl” refers to the vehicle control, 220  $\mu$ M NaOH. Each condition was performed in triplicate and repeated 3 times. \*\*\*\* denotes  $P < 0.0001$ .

### 3.3. In C2C12 cells, obtustatin inhibits $\alpha$ 1 $\beta$ 1 only

The inhibition dose curve assays were repeated with obtustatin (Fig. 3) and non-linear regression was used to analyse the curves as above. Here, obtustatin caused potent inhibition of the adhesion of  $\alpha$ 1 $\beta$ 1 (Fig. 3A) to GFOGER ( $IC_{50} = 0.45$   $\mu$ M,  $R^2 = 0.8920$ ,  $P < 0.0001$ ) and GLOGEN ( $IC_{50} = 0.96$   $\mu$ M,  $R^2 = 0.8496$ ,  $P < 0.0001$ ). The difference between inhibition on the two peptides was not significant. For the other transfected cells (Fig. 3B-D), no inhibition was observed. This suggests obtustatin is an efficient and specific inhibitor of full length  $\alpha$ 1 $\beta$ 1.

### 3.4. Adhesion of HT1080s is inhibited by TC-I-15 but not obtustatin

To confirm these findings in a second cell type, inhibition experiments were repeated by measuring the adhesion of HT1080 cells, which express  $\alpha$ 2 $\beta$ 1 but not  $\alpha$ 1 $\beta$ 1 (Ruggiero et al., 1996), to GFOGER (Fig. 4). Obtustatin had no effect on HT1080 adhesion (Fig. 4A). Notably, TC-I-15 inhibited the adhesion of HT1080 cells to GFOGER,  $P < 0.0001$  compared to vehicle control, and at lower concentrations than adhesion of C2C12- $\alpha$ 2 cells, with  $IC_{50}$  4.53  $\mu$ M and 26.77  $\mu$ M, respectively (Fig. 4B). HT1080 is a human fibrosarcoma line, and so expresses both the human  $\alpha$ - and  $\beta$ -subunits, whereas C2C12 cells are mouse myofibroblasts, stably transfected with the human  $\alpha$ -subunit that dimerises with the mouse  $\beta$ -subunit. Possibly TC-I-15 may have lower affinity for the mouse  $\beta$ -subunit, or the human-mouse heterodimer may communicate imperfectly. HT1080 cells may express lower levels of  $\alpha$ 2 $\beta$ 1, leading to lower avidity of binding to the peptide-coated surfaces. Any of these effects could explain the differences in  $IC_{50}$  values for TC-I-15 inhibition shown here.

### 3.5. Full-length, recombinant integrin $\alpha$ 3 $\beta$ 1 is not affected by TC-I-15


Here, TC-I-15 has been shown to have broader specificity of inhibition of  $\beta$ 1 integrins than reported to date. Since several other integrins contain the  $\beta$ 1 subunit (the laminin-binding integrins,  $\alpha$ 3 $\beta$ 1,  $\alpha$ 6 $\beta$ 1, and  $\alpha$ 7 $\beta$ 1, the RGD-binding integrins,  $\alpha$ 5 $\beta$ 1 and  $\alpha$ 8 $\beta$ 1, and the leukocyte integrins,  $\alpha$ 4 $\beta$ 1 and  $\alpha$ 9 $\beta$ 1), we considered that TC-I-15 might also inhibit

other  $\beta$ 1 integrins. As a representative example of such receptors, adhesion of full-length recombinant human  $\alpha$ 3 $\beta$ 1 was tested with TC-I-15, using laminin 511 as the substrate (Fig. 5). In these conditions, TC-I-15 showed no effect on  $\alpha$ 3 $\beta$ 1.

## 4. Discussion

Currently, TC-I-15 is available commercially as an inhibitor for  $\alpha$ 2 $\beta$ 1. Our results show that TC-I-15 is not specific, but has a broader specificity including  $\alpha$ 1 $\beta$ 1,  $\alpha$ 2 $\beta$ 1 and, at a much higher concentration,  $\alpha$ 11 $\beta$ 1. In contrast, TC-I-15 has, at best, slight effect on the adhesion of  $\alpha$ 10 $\beta$ 1 to GFOGER or GLOGEN peptides. The inhibition is substrate-dependent for  $\alpha$ 2 $\beta$ 1 and  $\alpha$ 11 $\beta$ 1, in that TC-I-15 inhibits adhesion to the lower-affinity GLOGEN at a much lower concentration than applies to GFOGER. The difference in potency of TC-I-15 inhibition of adhesion to these two ligands suggests a competition, where inhibition of adhesion to the higher-affinity GFOGER requires a higher concentration of TC-I-15 than inhibition of binding to GLOGEN. This suggests a reciprocal relationship between GFOGER binding to the upper surface of the  $\alpha$ I-domain and TC-I-15 recognition of its inhibitory site on the  $\beta$ I-domain. In contrast, the lower affinity GLOGEN does not require such a high concentration of TC-I-15 to achieve the same effect. Interestingly, this difference in potency is not seen for  $\alpha$ 1 $\beta$ 1, where both peptides are inhibited by similar concentrations of TC-I-15, presumably reflecting the similar affinity of  $\alpha$ 1 $\beta$ 1 for GLOGEN.

Crystal structures provide clear insight into the movement of helix 7 and the C-helix in the  $\alpha$ 2 I-domain upon binding of GFOGER (Emsley et al., 2000), and the ligation of E336 at the foot of helix 7 by the  $\beta$ -subunit MIDAS (Carafoli et al., 2013). The location of TC-I-15 binding close to the  $\alpha$ 2- $\beta$ 1 interface is also well described (Miller et al., 2009), and its effect is understood as allosteric, stabilising the inactive conformation of the integrin. The apparent competition between GFOGER or GLOGEN and TC-I-15 is, however, consistent with this allosteric model. Competition occurs between  $\alpha$ I E336 and TC-I-15 at the  $\beta$ I-domain MIDAS, while the role of the collagen peptide is to drive  $\alpha$ I helix 7 downwards closer to the  $\beta$ I MIDAS. In activated platelets, the affinity of  $\alpha$ 2 $\beta$ 1 for weaker ligands increases, whereas binding of the high



**Fig. 2.** Dose-dependent inhibition of integrin-mediated adhesion of C2C12 cells by TC-I-15. C2C12 cells stably expressing either A,  $\alpha$ 1 $\beta$ 1, B,  $\alpha$ 2 $\beta$ 1, C,  $\alpha$ 10 $\beta$ 1 or D,  $\alpha$ 11 $\beta$ 1 were tested for adhesion to GFOGER (blue) and GLOGEN (red) peptides as described in Materials and methods. NaOH (maximum concentration of 550  $\mu$ M) was included as a vehicle control on GFOGER (green) and GLOGEN (orange). Adhesion to GPP10 in the absence of inhibitor or vehicle control is shown as the baseline (purple). Adhesion is shown as Mean  $A_{490} \pm$  SD. Each condition was performed in triplicate and repeated three times. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

affinity GFOGER is less dependent upon cellular stimulation (Siljander et al., 2004). Thus, in resting cells, GFOGER can provide sufficient binding energy to trigger the reorganisation of the  $\alpha$ -subunit MIDAS, C-helix and helix 7 without inside-out integrin activation. This process must include the disruption of the E318 salt bridge, allowing helix 7 to translocate downwards towards the  $\beta$ -domain MIDAS. A weaker ligand for  $\alpha$ 2 $\beta$ 1, in this case GLOGEN, is unable to provide the same binding energy, and TC-I-15 is more readily able to inhibit  $\alpha$ 2 $\beta$ 1 by blockade of the helix 7- $\beta$  MIDAS interaction. Hence, helix 7 couples ligand binding at the  $\alpha$ -subunit MIDAS to competitive inhibition by TC-I-15 at the  $\beta$ -subunit MIDAS.


The question of selectivity of both TC-I-15 and obtustatin for the different collagen-binding integrins is more difficult to explain. We assume that both inhibitors must interact with both the  $\beta$ -domain MIDAS and part of the  $\alpha$ -subunit at the  $\alpha$ - $\beta$  interface. There is no crystal structure of an intact integrin that contains an  $\alpha$ I-domain, and although this interface has been modelled (Miller et al., 2009), no authentic data exists and the relationship between the  $\alpha$ I- and  $\beta$ I-domains is not clear. Inspection of the four  $\alpha$ I-domain sequences shows several differences in helices 1, 6 and 7, the region of the  $\alpha$  subunit most likely to contribute to the footprint of the inhibitors upon these integrins. These may contribute to the lower affinity of TCI-15 for  $\alpha$ 10 and  $\alpha$ 11 and for the very high selectivity of obtustatin.

We show here, through the use of recombinant  $\alpha$ I-domains, that


obtustatin does not compete directly with collagen at the  $\alpha$ I-domain. Instead, obtustatin may interact with  $\alpha$ 1 $\beta$ 1 in a similar way to other disintegrins, by binding to the  $\beta$ I-domain at or close to the  $\alpha$ - $\beta$  interface. The action of obtustatin could be analogous to that of TC-I-15, by stabilising both the inactive conformation of the  $\beta$ I-domain and blocking the reorganisation of helix 7 and the C-helix. Structural work is needed to clarify how the selectivity and potency of the active KTSL motif is achieved.

Given that TC-I-15 interacts primarily with the  $\beta$ 1 subunit to stabilise the inactive conformation of  $\alpha$ 1 $\beta$ 1 and  $\alpha$ 2 $\beta$ 1, we considered whether TC-I-15 might also inhibit other  $\beta$ 1 integrins that lack an  $\alpha$ I-domain. The previous report (Miller et al., 2009) had shown no effect of TC-I-15 on the adhesion of platelets, which express  $\alpha$ 5 $\beta$ 1 and  $\alpha$ 6 $\beta$ 1, to the RGD-containing ligands, fibronectin and fibrinogen. Here, we verify this specificity by showing that TC-I-15 had no effect on binding of full-length purified  $\alpha$ 3 $\beta$ 1 to the LDV-containing laminin-511, confirming that TC-I-15 is not a universal inhibitor of  $\beta$ 1 integrins. This reinforces the concept that the TC-I-15 interaction involves both the  $\beta$  subunit and the  $\alpha$ I-domain. However, the lack of effect on integrin  $\alpha$ 10 $\beta$ 1, which also contains an  $\alpha$ I-domain, suggests that the presence of both the  $\beta$ 1 subunit and an  $\alpha$ I-domain is not sufficient for inhibition to occur. The molecular detail of the interaction remains to be resolved.

In conclusion, it is imperative that integrin inhibitors are thoroughly tested for cross-reactivity before any therapeutic or research use.




**Fig. 3.** Dose-dependent inhibition of C2C12 cell adhesion to peptides by obtustatin. Cells expressed either A,  $\alpha 1\beta 1$ , B,  $\alpha 2\beta 1$ , C,  $\alpha 10\beta 1$  or D,  $\alpha 11\beta 1$ . Adhesion to GFOGER (blue) and GLOGEN (red) is shown, or to GPP10 in the absence of inhibitor or vehicle control (purple). Assays were performed as described in Materials and methods, and results are shown as Mean  $A_{490}$ ,  $\pm$  SD. Each condition was performed in triplicate and repeated three times. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)



**Fig. 4.** Dose-dependence of inhibition of HT1080 cell adhesion to GFOGER. Assays were performed as described in Material and methods; each inhibitor is shown in red and control curves in blue. The inhibitors under test were A, Obtustatin and B, TC-I-15. Adhesion is shown as Mean  $A_{490}$   $\pm$  SD. Each condition was performed in triplicate and repeated three times. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Obtustatin, in these conditions, was a potent and specific inhibitor for  $\alpha 1\beta 1$  adhesion to collagen peptides. The data presented here supports the use of obtustatin for the specific inhibition of  $\alpha 1\beta 1$  in cell-based assays, in-vivo assays or potential therapeutic settings. However,

because TC-I-15 inhibits  $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$  and, at high concentration,  $\alpha 11\beta 1$ , it must be used with caution in cellular environments where more than one of these integrins is present. TC-I-15 would be a useful tool when inhibition of both  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  is required, or where only one of these



**Fig. 5.** Static adhesion assay showing inhibition by TC-I-15 of full-length isolated  $\alpha 3\beta 1$  adhesion to placental laminin-511 or BSA. TC-I-15 (200  $\mu\text{M}$ ) is shown in black and the vehicle control data in light grey. Adhesion was quantified by an ELISA detecting the  $\beta 1$  subunit as described in Materials and methods, and is shown as Mean  $A_{450} \pm$  SD. Data were compared using 2-way ANOVA with Sidak's multiple comparison test, and differences between treatments were not significant. Each condition was performed in triplicate and repeated 3 times.

receptors is present. For example, TC-I-15 been proposed as a potential antithrombotic agent and has been used to block  $\alpha 2\beta 1$  on the surface of platelets to inhibit collagen-stimulated platelet aggregation (Miller et al., 2009). Platelets do not express  $\alpha 1\beta 1$  or  $\alpha 11\beta 1$  and so TC-I-15 would work well here as a specific inhibitor of  $\alpha 2\beta 1$ . However, in cell-based assays or in-vivo experiments, where more than one of the integrins  $\alpha 2\beta 1$ ,  $\alpha 1\beta 1$  and  $\alpha 11\beta 1$  are present, such as fibroblasts, endothelial cells or circulating cells such as leukocytes, the cross reactivity of TC-I-15 should be considered.

#### Declaration of Competing Interest

RWF is Chief Scientific Officer, CambCol Laboratories, Ely, Cambs, UK.

#### Acknowledgments

This study was funded by grants from the British Heart Foundation: SP/15/7/31561 to RF; RG/15/4/31268 to RF, and FS/15/20/31335 to RF and EH.

#### References

Alique, M., et al., 2014. Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation. *Clin. Sci. (Lond.)* 127 (1), 19–31.

Alonso, J.L., et al., 2002. Does the integrin alphaA domain act as a ligand for its betaA domain? *Curr. Biol.* 12 (10), R340–R342.

Arnaout, M.A., 2016. Biology and structure of leukocyte beta 2 integrins and their role in inflammation. *F1000Res* 5.

Arnaout, M.A., Mahalingam, B., Xiong, J.P., 2005. Integrin structure, allostery, and bidirectional signaling. *Annu. Rev. Cell Dev. Biol.* 21, 381–410.

Arruda Macedo, J.K., Fox, J.W., de Souza Castro, M., 2015. Disintegrins from snake venoms and their applications in cancer research and therapy. *Curr. Protein Pept. Sci.* 16 (6), 532–548.

Assoian, R.K., 1997. Anchorage-dependent cell cycle progression. *J. Cell Biol.* 136 (1), 1–4.

Assumpcao, T.C., Ribeiro, J.M., Francischetti, I.M., 2012. Disintegrins from hematophagous sources. *Toxins (Basel)* 4 (5), 296–322.

Barczyk, M., Carracedo, S., Gullberg, D., 2010. Integrins. *Cell Tissue Res.* 339 (1), 269–280.

Brown, M.C., et al., 2008. Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth. *Int. J. Cancer* 123 (9), 2195–2203.

Byzova, T.V., et al., 2000. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. *Mol. Cell* 6 (4), 851–860.

Calderwood, D.A., et al., 1999. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. *J. Biol. Chem.* 274 (40), 28071–28074.

Carafoli, F., et al., 2013. An activating mutation reveals a second binding mode of the integrin alpha2 I domain to the GFOGER motif in collagens. *PLoS One* 8 (7), e69833.

Chen, J., et al., 2002. The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. *Am. J. Pathol.* 161 (1), 337–344.

Coller, B.S., et al., 1989. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. *Blood* 74 (1), 182–192.

Daidone, I., et al., 2013. Structural and dynamical properties of KTS-disintegrins: a comparison between Obtustatin and Lebestatin. *Biopolymers* 99 (1), 47–54.

Dickeson, S.K., Santoro, S.A., 1998. Ligand recognition by the I domain-containing integrins. *Cell. Mol. Life Sci.* 54 (6), 556–566.

Emsley, J., et al., 1997. Crystal structure of the I domain from integrin alpha2beta1. *J. Biol. Chem.* 272 (45), 28512–28517.

Emsley, J., et al., 2000. Structural basis of collagen recognition by integrin alpha2beta1. *Cell* 101 (1), 47–56.

Farndale, R.W., 2019. Collagen-binding proteins: insights from the collagen toolkits. *Essays Biochem.* 63 (3), 337–348.

Farndale, R.W., et al., 2008. Cell-collagen interactions: the use of peptide toolkits to investigate collagen-receptor interactions. *Biochem. Soc. Trans.* 36 (Pt 2), 241–250.

Fassler, R., Meyer, M., 1995. Consequences of lack of beta 1 integrin gene expression in mice. *Genes Dev.* 9 (15), 1896–1908.

van der Flier, A., et al., 2010. Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development. *Development* 137 (14), 2439–2449.

Gardner, H., et al., 1996. Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. *Dev. Biol.* 175 (2), 301–313.

Giancotti, F.G., Ruoslahti, E., 1999. Integrin signaling. *Science* 285 (5430), 1028–1032.

Hamaia, S.W., et al., 2012. Mapping of potent and specific binding motifs, BIOGEN and GVOGEA, for integrin alpha1beta1 using collagen toolkits II and III. *J. Biol. Chem.* 287 (31), 26019–26028.

Hamaia, S.W., et al., 2017. Unique charge-dependent constraint on collagen recognition by integrin alpha10beta1. *Matrix Biol.* 59, 80–94.

Huveneers, S., Danen, E.H., 2009. Adhesion signaling - crosstalk between integrins, Src and Rho. *J. Cell Sci.* 122 (Pt 8), 1059–1069.

Hynes, R.O., 2002. Integrins: bidirectional, allosteric signaling machines. *Cell* 110 (6), 673–687.

Ibaragi, S., et al., 2011. Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin alpha1beta1 and alpha2beta1-p38 MAPK signaling. *Anticancer Res.* 31 (4), 1307–1313.

Kisiel, D.G., et al., 2004. Structural determinants of the selectivity of KTS-disintegrins for the alpha1beta1 integrin. *FEBS Lett.* 577 (3), 478–482.

Knight, C.G., et al., 2000. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. *J. Biol. Chem.* 275 (1), 35–40.

Luo, B.H., Carman, C.V., Springer, T.A., 2007. Structural basis of integrin regulation and signaling. *Annu. Rev. Immunol.* 25, 619–647.

Marcinkiewicz, C., et al., 2003. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. *Cancer Res.* 63 (9), 2020–2023.

Meredith Jr., J.E., Schwartz, M.A., 1997. Integrins, adhesion and apoptosis. *Trends Cell Biol.* 7 (4), 146–150.

Miller, M.W., et al., 2009. Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. *Proc. Natl. Acad. Sci. U. S. A.* 106 (3), 719–724.

Musiime, M., et al., Collagen assembly at the cell surface: dogmas revisited. *Cells*, 2021. 10(3).

Popov, C., et al., 2011. Integrins alpha2beta1 and alpha11beta1 regulate the survival of mesenchymal stem cells on collagen I. *Cell Death Dis.* 2, e186.

Popova, S.N., et al., 2007. Alpha11 beta1 integrin-dependent regulation of periodontal ligament function in the erupting mouse incisor. *Mol. Cell. Biol.* 27 (12), 4306–4316.

Pozzi, A., et al., 1998. Integrin alpha1beta1 mediates a unique collagen-dependent proliferation pathway in vivo. *J. Cell Biol.* 142 (2), 587–594.

Pozzi, A., et al., 2000. Elevated matrix metalloproteinase and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. *Proc. Natl. Acad. Sci. U. S. A.* 97 (5), 2202–2207.

Primac, I., et al., 2019. Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression. *J. Clin. Invest.* 129 (11), 4609–4628.

Raynal, N., et al., 2006. Use of synthetic peptides to locate novel integrin alpha2beta1-binding motifs in human collagen III. *J. Biol. Chem.* 281 (7), 3821–3831.

Ruggiero, F., et al., 1996. Structural requirements for alpha 1 beta 1 and alpha 2 beta 1 integrin mediated cell adhesion to collagen V. *J. Cell Sci.* 109 (Pt 7), 1865–1874.

San Antonio, J.D., et al., 2009. A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. *Am. J. Pathol.* 175 (3), 1338–1347.

Santala, P., Heino, J., 1991. Regulation of integrin-type cell adhesion receptors by cytokines. *J. Biol. Chem.* 266 (34), 23505–23509.

- Schwartz, M.A., Assoian, R.K., 2001. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. *J. Cell Sci.* 114 (Pt 14), 2553–2560.
- Senger, D.R., et al., 2002. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. *Am. J. Pathol.* 160 (1), 195–204.
- Shen, B., et al., 2019. Integrin alpha11 is an Osteoclast receptor and is required for the maintenance of adult skeletal bone mass. *Elife* 8.
- Shimaoka, M., Takagi, J., Springer, T.A., 2002. Conformational regulation of integrin structure and function. *Annu. Rev. Biophys. Biomol. Struct.* 31, 485–516.
- Siljander, P.R., et al., 2004. Integrin activation state determines selectivity for novel recognition sites in fibrillar collagens. *J. Biol. Chem.* 279 (46), 47763–47772.
- da Silva, R.G., et al., 2010. Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. *Am. J. Pathol.* 177 (3), 1534–1548.
- Sottnik, J.L., et al., 2013. Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis. *Clin. Exp. Metastasis* 30 (5), 569–578.
- Tadokoro, S., et al., 2003. Talin binding to integrin beta tails: a final common step in integrin activation. *Science* 302 (5642), 103–106.
- Takada, Y., Ye, X., Simon, S., 2007. The integrins. *Genome Biol.* 8 (5), 215.
- Tiger, C.F., et al., 2001. alpha11beta1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells. *Dev. Biol.* 237 (1), 116–129.
- Welf, E.S., Naik, U.P., Ogunnaik, B.A., 2012. A spatial model for integrin clustering as a result of feedback between integrin activation and integrin binding. *Biophys. J.* 103 (6), 1379–1389.
- Wondimu, Z., et al., 2006. Characterization of commercial laminin preparations from human placenta in comparison to recombinant laminins 2 (alpha2beta1gamma1), 8 (alpha4beta1gamma1), 10 (alpha5beta1gamma1). *Matrix Biol.* 25 (2), 89–93.
- Yang, W., et al., 2004. Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. *Proc. Natl. Acad. Sci. U. S. A.* 101 (9), 2906–2911.
- Zeltz, C., Gullberg, D., 2016. The integrin-collagen connection—a glue for tissue repair? *J. Cell Sci.* 129 (4), 653–664.
- Zeltz, C., et al., 2019. alpha11beta1 integrin is induced in a subset of cancer-associated fibroblasts in desmoplastic tumor stroma and mediates in vitro cell migration. *Cancers (Basel)* 11 (6).
- Zeltz, C., et al., 2020. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. *Semin. Cancer Biol.* 62, 166–181.
- Zhang, W.M., et al., 2003. Alpha 11beta 1 integrin recognizes the GFOGER sequence in interstitial collagens. *J. Biol. Chem.* 278 (9), 7270–7277.
- Zhang, Z., et al., 2008. alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. *Blood* 111 (4), 1980–1988.